NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis $4.98 -0.25 (-4.78%) Closing price 04:00 PM EasternExtended Trading$4.99 +0.01 (+0.12%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BioXcel Therapeutics Stock (NASDAQ:BTAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioXcel Therapeutics alerts:Sign Up Key Stats Today's Range$4.90▼$5.6050-Day Range$1.31▼$6.8052-Week Range$1.17▼$13.36Volume3.91 million shsAverage Volume5.09 million shsMarket Capitalization$30.18 millionP/E RatioN/ADividend YieldN/APrice Target$39.75Consensus RatingModerate Buy Company Overview BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Read More BioXcel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreBTAI MarketRank™: BioXcel Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 99th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingBioXcel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about BioXcel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($24.39) to ($16.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.84% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 24.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.13 Percentage of Shares Shorted4.84% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 24.62%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.52 News SentimentBioXcel Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for BioXcel Therapeutics this week, compared to 2 articles on an average week.Search Interest69 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 3,350% compared to the previous 30 days.MarketBeat Follows15 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.68% of the stock of BioXcel Therapeutics is held by institutions.Read more about BioXcel Therapeutics' insider trading history. Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Stock News HeadlinesBioxcel Therapeutics Files Prospectus for $80M Share SaleAugust 21 at 2:39 AM | theglobeandmail.comAnalysts Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Target Price at $39.75August 21 at 2:17 AM | americanbankingnews.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)Bioxcel Therapeutics (BTAI) Receives a Buy from Canaccord GenuityAugust 20 at 4:21 PM | theglobeandmail.comBioXcel Therapeutics announces pre-sNDA meeting responses from FDAAugust 19 at 10:33 AM | msn.comBioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaAugust 19 at 7:00 AM | globenewswire.comBioXcel stock surges after positive FDA feedback on BXCL501 expansionAugust 18, 2025 | investing.comBioXcel Shares Jump After Encouraging FDA Feedback on BXCL501 Home-Use ExpansionAugust 18, 2025 | msn.comSee More Headlines BTAI Stock Analysis - Frequently Asked Questions How have BTAI shares performed this year? BioXcel Therapeutics' stock was trading at $5.9824 at the beginning of 2025. Since then, BTAI stock has decreased by 16.8% and is now trading at $4.98. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) released its earnings results on Tuesday, August, 12th. The company reported ($2.45) EPS for the quarter, missing analysts' consensus estimates of ($2.30) by $0.15. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.21 million. When did BioXcel Therapeutics' stock split? BioXcel Therapeutics shares reverse split on the morning of Monday, February 10th 2025.The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' top institutional shareholders include Oaktree Capital Management LP (3.98%), Murchinson Ltd. (1.33%), Oaktree Fund Advisors LLC (0.71%) and Geode Capital Management LLC (0.47%). Insiders that own company stock include Vimal Mehta, Richard I Steinhart, Vincent O'neill, Matthew T Wiley, Frank Yocca and Krishnan Nandabalan. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA). Company Calendar Last Earnings8/12/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTAI CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees90Year Founded2017Price Target and Rating Average Price Target for BioXcel Therapeutics$39.75 High Price Target$80.00 Low Price Target$4.00 Potential Upside/Downside+697.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($12.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.60 million Net Margins-5,869.82% Pretax Margin-5,869.82% Return on EquityN/A Return on Assets-134.45% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.74 Sales & Book Value Annual Sales$2.27 million Price / Sales13.31 Cash FlowN/A Price / Cash FlowN/A Book Value($17.78) per share Price / Book-0.28Miscellaneous Outstanding Shares6,060,000Free Float4,772,000Market Cap$30.21 million OptionableOptionable Beta0.05 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BTAI) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.